+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 10Years - 17Years
All Genders
ID06372964

Evaluating Lumateperone for Major Depressive Episodes in Children and Teens With Bipolar I or II Disorder A Randomized, Placebo-Controlled Multicenter Study

Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03

384

Participants Needed

68

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of lumateperone in children and teenagers aged 10 to 17 who have major depressive episodes linked to bipolar I or bipolar II disorder. This is a multicenter, randomized, double-blind study comparing lumateperone to a placebo to understand its potential impact on bipolar depression in pediatric patients. The diagnosis is confirmed using a structured psychiatric interview following DSM-5 criteria. Participants will take either lumateperone or a matching placebo once daily during a 6-week double-blind treatment period. Dosage varies by age, with patients aged 13 to 17 receiving 42 mg and those aged 10 to 12 receiving 21 mg. The study is divided into three phases an initial screening period of up to 2 weeks, the 6-week treatment phase, and a 1-week safety follow-up after the last dose. During the study, participants will undergo assessments including the Childrens Depression Rating Scale-Revised CDRS-R to measure depression severity. Safety will be monitored throughout the trial with a follow-up visit about one week after treatment ends. The study aims to evaluate changes in depressive symptoms over the 6-week treatment, with all visits and assessments scheduled accordingly.

CONDITIONS

Brief Title

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here